Trials / Completed
CompletedNCT02779764
A Long Term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoieses Stimulating Agent (ESA) Treatment
A Phase 3, Long-term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoiesis Stimulating Agent Treatment
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 164 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the efficacy and safety of ASP1517 in hemodialysis patients with renal anemia whose treatment is converted from an Erythropoieses Stimulating Agent formulation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | roxadustat | Oral |
Timeline
- Start date
- 2016-05-16
- Primary completion
- 2017-05-16
- Completion
- 2017-11-28
- First posted
- 2016-05-20
- Last updated
- 2024-10-31
Locations
25 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02779764. Inclusion in this directory is not an endorsement.